Treatment of malignant mesothelioma with epirubicin and ifosfamide

M. D. Magri, S. Foladore, A. Veronesi, C. Serra, M. Nicotra, M. Tommasi, G. Grandi, S. Monfardini, C. Bianchi

Research output: Contribution to journalArticlepeer-review


From May 1988 to March 1990, 17 consecutive patients with histologically proven malignant mesothelioma were treated with epirubicin 75 mg/sqm i.v. on day 1 and ifosfamide 1.8 gr/sqm/day i.v. from day 1-5. Treatment was repeated every 3 weeks until progression. Fifty-three chemotherapy cycles were administered to the 17 patients treated (median, 3 cycles/patient). No complete responses, 1 partial response, 8 stable diseases and 8 progressions were noted. Toxocity was acceptable and no treatment-related deaths occurred. Actuarial median survival was 6 months. In this study, a combination of full doses of epirubicin and ifosfamide did not prove to be active in malignant mesothelioma.

Original languageEnglish
Pages (from-to)237-238
Number of pages2
JournalAnnals of Oncology
Issue number3
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology


Dive into the research topics of 'Treatment of malignant mesothelioma with epirubicin and ifosfamide'. Together they form a unique fingerprint.

Cite this